Published: Guidance, quality standards and advice
Showing 11 to 16 of 16
Title | Reference number | Published | Last updated |
---|---|---|---|
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | ||
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | ||
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | ||
Endometriosis | QS172 | ||
Community pharmacies: promoting health and wellbeing | NG102 | ||
Dupilumab for treating moderate to severe atopic dermatitis | TA534 |